![Renata Pasqualini](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Isan Chen | M | 61 |
Mbrace Therapeutics, Inc.
![]() Mbrace Therapeutics, Inc. BiotechnologyHealth Technology Mbrace Therapeutics, Inc. is an American company that specializes in antibody discovery methodology. The company's approach, called SPARTA, overcomes several challenges to generate human antibodies that can be quickly translated into clinical applications. Mbrace Therapeutics was founded by Renata Pasqualini, Isan Chen, and Wadih Arap, with Isan Chen serving as the CEO since incorporation. | 4 years |
Wadih Arap | M | - |
Mercator Therapeutics, Inc.
![]() Mercator Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mercator Therapeutics develops novel cancer drugs. It is the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs. The company was founded by Wadih Arap, Renata Pasqualini, Roy Lobb, Mark Leuchtenberger, and Christopher Guiffre in 2009 is headquartered in Wellesley, MA.
Mbrace Therapeutics, Inc.
![]() Mbrace Therapeutics, Inc. BiotechnologyHealth Technology Mbrace Therapeutics, Inc. is an American company that specializes in antibody discovery methodology. The company's approach, called SPARTA, overcomes several challenges to generate human antibodies that can be quickly translated into clinical applications. Mbrace Therapeutics was founded by Renata Pasqualini, Isan Chen, and Wadih Arap, with Isan Chen serving as the CEO since incorporation. | 4 years |
Jason Rifkin | M | 46 |
PhageNova Bio, Inc.
![]() PhageNova Bio, Inc. BiotechnologyHealth Technology PhageNova Bio, Inc. is a biotechnology company that is developing a modular, bacteriophage-based platform for targeted gene expression in cancer, vaccination, and molecular imaging. PhageNova Bio is based in Scarsdale, NY. The company's lead cancer construct is designed to selectively target tumor-associated blood vessels and tumor cells, resulting in the expression of TNF-?, an anti-tumor agent, specifically and exclusively in tumors. The company has extensively validated tumor targeting and selective gene expression capabilities, and therapeutic efficacy was observed in the absence of dose-limiting toxicity in multiple species and several tumor models. The company was founded by Renata Pasqualini, Wadih Arap, Steven K. Libutti, Juri G. Gelovani, and the CEO is Jason A. Rifkin. | - |
Steven K. Libutti | M | - |
PhageNova Bio, Inc.
![]() PhageNova Bio, Inc. BiotechnologyHealth Technology PhageNova Bio, Inc. is a biotechnology company that is developing a modular, bacteriophage-based platform for targeted gene expression in cancer, vaccination, and molecular imaging. PhageNova Bio is based in Scarsdale, NY. The company's lead cancer construct is designed to selectively target tumor-associated blood vessels and tumor cells, resulting in the expression of TNF-?, an anti-tumor agent, specifically and exclusively in tumors. The company has extensively validated tumor targeting and selective gene expression capabilities, and therapeutic efficacy was observed in the absence of dose-limiting toxicity in multiple species and several tumor models. The company was founded by Renata Pasqualini, Wadih Arap, Steven K. Libutti, Juri G. Gelovani, and the CEO is Jason A. Rifkin. | - |
Timothy Rothwell | M | 73 |
PhageNova Bio, Inc.
![]() PhageNova Bio, Inc. BiotechnologyHealth Technology PhageNova Bio, Inc. is a biotechnology company that is developing a modular, bacteriophage-based platform for targeted gene expression in cancer, vaccination, and molecular imaging. PhageNova Bio is based in Scarsdale, NY. The company's lead cancer construct is designed to selectively target tumor-associated blood vessels and tumor cells, resulting in the expression of TNF-?, an anti-tumor agent, specifically and exclusively in tumors. The company has extensively validated tumor targeting and selective gene expression capabilities, and therapeutic efficacy was observed in the absence of dose-limiting toxicity in multiple species and several tumor models. The company was founded by Renata Pasqualini, Wadih Arap, Steven K. Libutti, Juri G. Gelovani, and the CEO is Jason A. Rifkin. | - |
Robert More | M | 56 |
Mbrace Therapeutics, Inc.
![]() Mbrace Therapeutics, Inc. BiotechnologyHealth Technology Mbrace Therapeutics, Inc. is an American company that specializes in antibody discovery methodology. The company's approach, called SPARTA, overcomes several challenges to generate human antibodies that can be quickly translated into clinical applications. Mbrace Therapeutics was founded by Renata Pasqualini, Isan Chen, and Wadih Arap, with Isan Chen serving as the CEO since incorporation. | - |
Racquel Bracken | F | 41 |
Mbrace Therapeutics, Inc.
![]() Mbrace Therapeutics, Inc. BiotechnologyHealth Technology Mbrace Therapeutics, Inc. is an American company that specializes in antibody discovery methodology. The company's approach, called SPARTA, overcomes several challenges to generate human antibodies that can be quickly translated into clinical applications. Mbrace Therapeutics was founded by Renata Pasqualini, Isan Chen, and Wadih Arap, with Isan Chen serving as the CEO since incorporation. | 3 years |
Keith D. Greenfield | M | - |
PhageNova Bio, Inc.
![]() PhageNova Bio, Inc. BiotechnologyHealth Technology PhageNova Bio, Inc. is a biotechnology company that is developing a modular, bacteriophage-based platform for targeted gene expression in cancer, vaccination, and molecular imaging. PhageNova Bio is based in Scarsdale, NY. The company's lead cancer construct is designed to selectively target tumor-associated blood vessels and tumor cells, resulting in the expression of TNF-?, an anti-tumor agent, specifically and exclusively in tumors. The company has extensively validated tumor targeting and selective gene expression capabilities, and therapeutic efficacy was observed in the absence of dose-limiting toxicity in multiple species and several tumor models. The company was founded by Renata Pasqualini, Wadih Arap, Steven K. Libutti, Juri G. Gelovani, and the CEO is Jason A. Rifkin. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Roy R. Lobb | M | - |
Mercator Therapeutics, Inc.
![]() Mercator Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mercator Therapeutics develops novel cancer drugs. It is the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs. The company was founded by Wadih Arap, Renata Pasqualini, Roy Lobb, Mark Leuchtenberger, and Christopher Guiffre in 2009 is headquartered in Wellesley, MA. | 3 years |
Mark Leuchtenberger | M | 67 |
Mercator Therapeutics, Inc.
![]() Mercator Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mercator Therapeutics develops novel cancer drugs. It is the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs. The company was founded by Wadih Arap, Renata Pasqualini, Roy Lobb, Mark Leuchtenberger, and Christopher Guiffre in 2009 is headquartered in Wellesley, MA. | 3 years |
Christopher Guiffre | M | 56 |
Mercator Therapeutics, Inc.
![]() Mercator Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mercator Therapeutics develops novel cancer drugs. It is the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs. The company was founded by Wadih Arap, Renata Pasqualini, Roy Lobb, Mark Leuchtenberger, and Christopher Guiffre in 2009 is headquartered in Wellesley, MA. | 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 11 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Renata Pasqualini
- Personal Network